Advancements in Dermatology: A Weekly Review
Dermatologia e Venerologia
Advances in Dermatology: From Tinea Capitis to Alopecia Areata
This week we cover new guidelines for tinea capitis management, promising results for JAK inhibitors in alopecia areata, infection risks with JAK-STAT inhibitors, and innovative approaches to melanoma and hereditary angioedema treatment.
Accedi o Registrati per ascoltare questo episodio
Bibliografia
1. Consensus-based Guideline on tinea capitis.
Authors: Mayser P, Abeck D, Bosshard PP, et al.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026 Oct
PMID: 42444404
DOI: 10.1111/ddg.70395x
2. Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.
Authors: Mostaghimi A, Gooderham MJ, Lynde C, et al.
Journal: JAMA dermatology, 2026 Oct 1
PMID: 42584887
DOI: 10.1001/jamadermatol.2026.2853
3. Large-scale meta-analysis of infection risk with JAK-STAT inhibitors in 29,000 patients.
Authors: Krebs M, Gulyás L, Fazekas KK, et al.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 Oct
PMID: 42187316
DOI: 10.1111/jdv.70508
4. International Dermoscopy Society consensus recommendations for the management of lentigo maligna.
Authors: Forsea AM, Pampena R, Akay BN, et al.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 Oct
PMID: 41854120
DOI: 10.1111/jdv.70406
5. Crusted scabies following tralokinumab and systemic corticosteroid treatment for presumed atopic dermatitis.
Authors: Turan TL, Rochín LMC, Blume-Peytavi U, et al.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026 Oct
PMID: 42462997
DOI: 10.1016/j.ijid.2026.108984
6. The Gut Microbiome as a Therapeutic Target in Alopecia Areata: Not Yet Part of the Patient Treatment Plan.
Authors: McMullen E, Hafeez DA, Pai N, et al.
Journal: International journal of dermatology, 2026 Oct
PMID: 41999025
DOI: 10.1111/ijd.70437
7. Psychoeducational schema therapy for psoriasis and atopic dermatitis: a randomized controlled pilot crossover trial.
Authors: von Spreckelsen R, Emmert H, Hartmann J, et al.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026 Oct
PMID: 41854066
DOI: 10.1111/ddg.70020
8. Advantages and limitations of in vitro models for atopic dermatitis: A consensus expert opinion.
Authors: Peters RHW, Smits JPH, van den Bogaard EH, et al.
Journal: The Journal of investigative dermatology, 2026 Oct
PMID: 42246919
DOI: 10.1016/j.jid.2026.04.032
9. Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.
Authors: Hauschild A, Hassel JC, Ziemer M, et al.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026 Oct
PMID: 42579833
DOI: 10.1200/JCO-26-00852
10. Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.
Authors: Riedl MA, Li PH, Adatia A, et al.
Journal: Lancet (London, England), 2026 Oct 24
PMID: 42849489
DOI: 10.1016/S0140-6736(26)01296-1
Authors: Mayser P, Abeck D, Bosshard PP, et al.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026 Oct
PMID: 42444404
DOI: 10.1111/ddg.70395x
2. Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.
Authors: Mostaghimi A, Gooderham MJ, Lynde C, et al.
Journal: JAMA dermatology, 2026 Oct 1
PMID: 42584887
DOI: 10.1001/jamadermatol.2026.2853
3. Large-scale meta-analysis of infection risk with JAK-STAT inhibitors in 29,000 patients.
Authors: Krebs M, Gulyás L, Fazekas KK, et al.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 Oct
PMID: 42187316
DOI: 10.1111/jdv.70508
4. International Dermoscopy Society consensus recommendations for the management of lentigo maligna.
Authors: Forsea AM, Pampena R, Akay BN, et al.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 Oct
PMID: 41854120
DOI: 10.1111/jdv.70406
5. Crusted scabies following tralokinumab and systemic corticosteroid treatment for presumed atopic dermatitis.
Authors: Turan TL, Rochín LMC, Blume-Peytavi U, et al.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026 Oct
PMID: 42462997
DOI: 10.1016/j.ijid.2026.108984
6. The Gut Microbiome as a Therapeutic Target in Alopecia Areata: Not Yet Part of the Patient Treatment Plan.
Authors: McMullen E, Hafeez DA, Pai N, et al.
Journal: International journal of dermatology, 2026 Oct
PMID: 41999025
DOI: 10.1111/ijd.70437
7. Psychoeducational schema therapy for psoriasis and atopic dermatitis: a randomized controlled pilot crossover trial.
Authors: von Spreckelsen R, Emmert H, Hartmann J, et al.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026 Oct
PMID: 41854066
DOI: 10.1111/ddg.70020
8. Advantages and limitations of in vitro models for atopic dermatitis: A consensus expert opinion.
Authors: Peters RHW, Smits JPH, van den Bogaard EH, et al.
Journal: The Journal of investigative dermatology, 2026 Oct
PMID: 42246919
DOI: 10.1016/j.jid.2026.04.032
9. Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.
Authors: Hauschild A, Hassel JC, Ziemer M, et al.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026 Oct
PMID: 42579833
DOI: 10.1200/JCO-26-00852
10. Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.
Authors: Riedl MA, Li PH, Adatia A, et al.
Journal: Lancet (London, England), 2026 Oct 24
PMID: 42849489
DOI: 10.1016/S0140-6736(26)01296-1
